Prosus has officially announced a €400 million (US$460 million) investment into Alan, a prominent European leader in the health and insurance technology sector. This latest funding round elevates the company’s valuation to €5.5 billion (US$6.3 billion). The capital injection is structured to include both primary and secondary equity. Prosus is joined in this financial round by existing backers Teachers’ Venture Growth (TVG) and Index Ventures, alongside new participant Dara Holdings. The Prosus Alan investment occurs at a time when artificial intelligence is fundamentally reshaping how individuals access and interact with medical services. Alan has developed an AI-native healthcare platform that integrates insurance, care, and preventative measures into a single, personalized user experience. As of the first quarter of 2026, the company reported an Annual Recurring Revenue exceeding €800 million, representing a 53% increase year-on-year, while achieving profitability in its largest market, France.
The company currently provides services to more than 1.1 million individuals and has demonstrated significant operating leverage by scaling its operations with limited headcount growth. This partnership is expected to yield mutual strategic advantages, as Prosus intends to support the scaling of the consumer ecosystem and facilitate expansion into large international territories where Prosus maintains a strong presence. Furthermore, the collaboration will accelerate AI-led product development, granting Alan access to the Prosus Large Commerce Model (LCM). This move aligns with the life assistant strategy of the investor, aiming to broaden its reach within the healthcare domain. The completion of the Prosus Alan investment remains contingent upon receiving necessary regulatory approvals, including those required by the relevant financial authorities in France.
Executive Perspectives on the Partnership
“Healthcare presents one of the most significant global opportunities for AI-led transformation,” stated Fahd Beg, Head of Investments at Prosus Group. “Alan has built something unique: an integrated platform where insurance, prevention and care delivery reinforce each other, creating an exceptional healthcare experience for consumers and outstanding platform engagement. We’re excited to partner with Alan to accelerate its international expansion and unlock value through our ecosystem.”
Jean-Charles Samuelian-Werve, Co-founder and CEO of Alan, emphasized the urgency of modernizing medical access: “Health can’t wait, not for symptoms to get worse, not for a six-month appointment, not for the system to catch up. Yet that is exactly how healthcare works today. We believe great health is a universal right, and that prevention should be too. For ten years we have shown that technology can turn healthcare from reactive to proactive, helping people act early instead of reacting late. That is what prevention insurance is, and it’s the category we are building. We selected Prosus for their very deep expertise in international expansion and consumer products and to benefit from the incredible ecosystem they are building. We are still at the very beginning of what Alan can become.” As the company moves forward, it will continue to manage its consumer ecosystem and life assistant strategy to maintain its market position while awaiting final clearance from financial authorities. The firm’s ability to maintain headcount growth at a controlled rate while utilizing primary and secondary equity for expansion remains a core component of its operational model.
